Covovax jab for children to be ready for use within six months
According to Poonawalla, the jab is developed with the assistance of the US biotechnology company Novavax. The third round of trials of Covovax is progressing and it has yielded good results.
According to Poonawalla, the jab is developed with the assistance of the US biotechnology company Novavax. The third round of trials of Covovax is progressing and it has yielded good results.
According to Poonawalla, the jab is developed with the assistance of the US biotechnology company Novavax. The third round of trials of Covovax is progressing and it has yielded good results.
New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla said on Tuesday that his firm would launch a new vaccine for children, Covovax, to resist coronavirus disease. Covovax can be used by anyone above the age of three years.
According to Poonawalla, the jab is developed with the assistance of the US biotechnology company Novavax. The third round of trials of Covovax is progressing and it has yielded good results.
At the moment, Covishield, which is found to be very effective among adults, is not approved in people below the age of 18. This is the reason why Covovax is under trial. It has shown excellent results as of now, Poonawalla said.
Though permission was granted by the authorities for the use of Zydus Cadila's ZyCov-D among children in the country, the distribution of the vaccine has not yet begun.